
TARS • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold TARS in your mock portfolio yet.
Tarsus Pharmaceuticals has shown strong financial performance with its revenue growing by 268% year over year to $48.1M in the last quarter. Similarly, gross profit surged by 278.4% YoY to reach $44.9M, indicating a healthy margin level for the company. However, it's important to note that operating income is still negative at -$25.2M but has improved by 43.4% YoY indicating that the company is working towards profitability.
The stock price of Tarsus Pharmaceuticals is currently trading at $52.69 and has seen an impressive growth of 138.4% YoY and a slight increase of 0.4% in the last month alone which shows investor confidence in the company's prospects despite its negative PE ratio of -14.05 and EPS of -3.75 suggesting high future earnings growth expectations from investors.
In terms of alternative data signals, web traffic has decreased significantly by -61.% MoM which could be a potential red flag as it might indicate declining interest or engagement with the company's products or services online but this needs further investigation before drawing any conclusions.
On a positive note, job postings have increased significantly by 50% MoM and up by 84.6% YoY signifying business expansion plans while social media followership on Twitter, Instagram and Facebook have also been increasing steadily over time which indicates improving brand awareness among consumers.
In conclusion, based on Tarsus Pharmaceuticals' solid revenue growth, steady stock price appreciation despite current lack of profitability and mixed alternative data signals (increasing job postings & social media followers but decreasing web traffic), the outlook for Tarsus Pharmaceuticals' stock is cautiously bullish.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: